Favorable News Coverage Extremely Likely to Affect Myriad Genetics (MYGN) Stock Price

Media headlines about Myriad Genetics (NASDAQ:MYGN) have trended positive recently, InfoTrie reports. The research group identifies negative and positive media coverage by analyzing more than 6,000 blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Myriad Genetics earned a news impact score of 2.17 on their scale. InfoTrie also gave news stories about the company an news buzz score of 10 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company’s share price in the near future.

These are some of the news stories that may have impacted Myriad Genetics’ analysis:

MYGN traded down $1.66 during trading on Thursday, hitting $31.16. The company’s stock had a trading volume of 1,449,563 shares, compared to its average volume of 774,804. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.86 and a current ratio of 3.19. Myriad Genetics has a 12 month low of $27.27 and a 12 month high of $50.44. The company has a market cap of $2.74 billion, a price-to-earnings ratio of 25.97, a PEG ratio of 2.26 and a beta of 0.51.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings data on Tuesday, November 6th. The company reported $0.43 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.30 by $0.13. Myriad Genetics had a return on equity of 10.49% and a net margin of 7.07%. The firm had revenue of $202.30 million during the quarter, compared to the consensus estimate of $203.20 million. During the same quarter in the previous year, the company posted $0.26 EPS. The business’s revenue for the quarter was up 13.1% compared to the same quarter last year. As a group, research analysts predict that Myriad Genetics will post 1.41 EPS for the current fiscal year.

Several brokerages have recently weighed in on MYGN. Zacks Investment Research lowered Myriad Genetics from a “buy” rating to a “hold” rating in a report on Monday, October 29th. BidaskClub downgraded Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Saturday, November 3rd. Deutsche Bank raised their target price on Myriad Genetics from $37.00 to $43.00 and gave the stock a “hold” rating in a research report on Monday. Piper Jaffray Companies raised their target price on Myriad Genetics to $38.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 22nd. Finally, Barclays raised their target price on Myriad Genetics from $35.00 to $38.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 22nd. Three analysts have rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $41.90.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by WKRB News and is the sole property of of WKRB News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.wkrb13.com/2018/11/09/favorable-news-coverage-extremely-likely-to-affect-myriad-genetics-mygn-stock-price.html.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Featured Article: Technical Analysis of Stocks and What It Means

Insider Buying and Selling by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply